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of end-stage liver disease. Although the surgical approaches have
substantially increased the success rate of liver transplantation,
there are still a number of obstacles to encounter after liver
transplantation. One of them is kidney disease. According to
previous reports, liver transplant recipients have a high rate of
kidney disease, reaching 80% [1]. The major renal presentation
includes acute kidney injury (AKI) and chronic kidney disease
(CKD), and both AKI and CKD in liver transplant recipients may
lead to end-stage renal disease and increase the risk of cardiovas-
cular disease and mortality. The occurrence of AKI and CKD has
remained relatively unchanged despite increased awareness of
kidney problems after liver transplantation.
Perioperative problems can affect kidney function in liver
transplant recipients. Among them, renal hemodynamic issues
are frequently observed during the early period of liver transplan-
tation: surgery-related events, blood losses, hypotension, sepsis,
cardiac dysfunction, and volume depletion [2]. It is well known
that a decrease in mean arterial pressure (approximatelyo
70mmHg) may induce kidney damage. Accordingly, keeping
postoperative ﬂuid balance through adequate ﬂuid resuscitation
is an important measure for a better early outcome.
These hemodynamic issues can be reviewed from the medical
records.
It was previously reported that most cases of CKD following
liver transplantation were attributable to nephrotoxicity induced
by calcineurin inhibitors (CNIs) [3]. CNIs including tacrolimus and
cyclosporine may produce afferent and efferent arteriolar vaso-
constriction in the kidney, although they have a great effect on
graft survival. Alternative immunosuppressive regimens have
emerged: mycophenolate mofetil and inhibitors of mammalian
target of rapamycin. However, there is insufﬁcient evidence that
better or comparable outcomes are achieved by these alternative
regimens compared to CNI regimens [4,5]. Accordingly, CNI is
currently the backbone of immunosuppressive regimens following
liver transplantation. Also, CNI-induced nephrotoxicity should
always be considered in the clinical settings where liver transplant
recipients have a decreased kidney function.
In the current issue of Kidney Research and Clinical Practice,
Lee at al investigated histological ﬁndings of the kidney from 10
liver transplant recipients with decreased kidney function [9].
The most common diagnosis was glomerulonephritis (GN) such
as immunoglobulin A nephropathy (n¼4), mesangial prolifera-
tive GN (n¼1), focal proliferative GN (n¼1), and membranous
GN (n¼1). Typical CNI-induced nephrotoxicity was diagnosed in
three cases. All of the patients had received CNI regimens.32/$ - see front matter & 2013. The Korean Society of Nephrology. Publi
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
x.doi.org/10.1016/j.krcp.2013.10.003some clinical implications. First, the proportion of patients
with CNI-induced nephrotoxicity was modest. Rather, GN was
the most prevalent cause of kidney disease in that study subset.
This ﬁnding is not different from the results of other study
groups [6–8], in which histology was not limited to CNI-induced
nephrotoxicity. The GN may have resulted from the progression
of pre-existing GN or new development after liver transplanta-
tion. Although the origin of GN is not fully established by these
studies, it is important that the management of GN is signiﬁ-
cantly different from that of CNI-induced nephrotoxicity. In this
regard, kidney biopsy may be considered as essential to differ-
entiate the causes of kidney disease in liver transplant recipients.
Fortunately, there were no complications after kidney biopsy,
although selection bias for indication is unavoidable.
As stated above, a kidney biopsy can reveal a hidden
pathology or cause of kidney disease following liver trans-
plantation. However, a kidney biopsy is not essential in all the
cases with decreased kidney function because there is no
evidence that a kidney biopsy improves the kidney or patient
outcomes in liver transplant recipients. Additionally, a success-
ful kidney biopsy, which means that biopsy specimen is
properly reviewed and there are no signiﬁcant complications,
cannot be done properly without an experienced practitioner.
In summary, recent studies including the cases described by
Lee et al [9] suggest that we need to ﬁnd causes other than CNI-
induced nephrotoxicity in liver transplant recipients with kidney
disease. Although some issues hamper the use of a kidney biopsy
in routine clinical practice, kidney biopsies for selected patients
are required to diagnose and manage the underlying kidney
disease properly. Furthermore, kidney biopsies in some patients
are warranted to predict the prognosis because liver transplant
recipients with kidney disease could have a worse outcome. For
these reasons, future studies should address and determine the
indication for kidney biopsy in liver transplant recipients.Conﬂicts of interest
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